SecProbe.io

December 15, 2024
Mitchell Creem
Chief Executive Officer
Pioneer Acquisition I Corp
131 Concord Street
Brooklyn, NY 11201
Re:Pioneer Acquisition I Corp
Draft Registration Statement on Form S-1
Submitted November 18, 2024
CIK No.: 0002040381
Dear Mitchell Creem:
            We have reviewed your draft registration statement and have the following comments.
            Please respond to this letter by providing the requested information and either
submitting an amended draft registration statement or publicly filing your registration
statement on EDGAR. If you do not believe a comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
            After reviewing the information you provide in response to this letter and your
amended draft registration statement or filed registration statement, we may have additional
comments.
Draft Registration Statement on Form S-1
Cover Page
1.Please revise to clarify whether public shareholders may elect to redeem their shares if
they abstain from voting. Also revise to clarify if there are other limitations on
redemption rights. For example, we note your disclosure elsewhere, including on page
41, indicating that redemptions cannot cause net tangible assets to fall below
$5,000,001. See Item 1602(a)(2) of Regulation S-K.
When discussing the amount of compensation received or to be received, as required
by Item 1602(a)(3) of Regulation S-K, please include the repayment of various loans
to the sponsor, including a discussion of the possible issuance of private placement
warrants upon conversion of up to $1,500,000 of loans at a price of $1.00 per warrant,
and any compensation paid or to be paid to or securities issued or to be issued to 2.

December 15, 2024
Page 2
sponsor affiliates and promoters and the price paid. Please also provide a cross-
reference to all relevant sections in the prospectus for disclosures related to
compensation, highlighted by prominent type or in another manner, as required by
Item 1602(a)(3) of Regulation S-K.
3.Please revise your cross-reference to related dilution disclosures to highlight by
prominent type or in another manner. See Item 1602(a)(4) of Regulation S-K. Also
highlight your cross-reference to the risk factors section with prominent type or in
another manner. See Item 501(b)(5) of Regulation S-K.
4.Please clearly state that there may be actual or potential material conflicts of interest
between the sponsor, its affiliates, or promoters; and purchasers in the offering. Please
also include cross-references to all related disclosures in the prospectus, highlighted
by prominent type or in another manner. See Item 1602(a)(5) of Regulation S-K.
5.Where you discuss the non-managing sponsor investors' expression of interest, please
revise to clarify whether their potential purchase of units in the offering is conditioned
on their potential indirect purchase of private placement warrants and founder shares
in a private placement, or vice versa. In addition, we note your disclosures that such
investors will purchase up to 4,010,000 private placement warrants to be purchased by
your "sponsor, Cantor and Odeon." Please revise to clarify whether these investors'
warrants will all be from the 4,955,000 private placement warrants allocated to the
sponsor rather than the  2,545,000 private placement warrants allocated to the
underwriters.
Our Insiders and Management, page 3
6.We note that Mitchell Creem is the manager of your sponsor and has voting and
dispositive power over the shares owned by Pioneer Acquisition 1 Sponsor Holdco
LLC. We also note that the non-managing sponsor members will hold membership
interests in the sponsor, and your disclosure on page 52 that all your officers and
directors own individual economic interests in your sponsor. Please revise to disclose
all persons or affiliated groups who have direct or indirect material interests in the
sponsor, as well as the nature and amount of their interests. See Item 1603(a)(7) of
Regulation S-K.
7.Please disclose any circumstances or arrangements under which the sponsor, its
affiliates and promoters, directly or indirectly have transferred or could transfer
ownership of your securities or that have resulted or could result in the surrender or
cancellation of such securities. Specifically, disclose whether indirect transfers of
ownership of your securities could take place through the transfer of membership
interests in the sponsor itself and describe any circumstances or arrangements
whereby this has or may take place. See Item 1603(a)(6) of Regulation S-K.
Prospectus Summary
Competitive Strengths, page 6
We refer to your statement that your management team and board "boasts a
remarkable track record of identifying and sourcing blank-check transactions," and
that their previous SPAC business combination experience demonstrate
strengths. Please revise to balance your disclosures to disclose that several of the 8.

December 15, 2024
Page 3
SPACs did not complete their initial public offerings, as your disclosures indicate on
page 137, and that Altitude Acquisition Corp has been delisted from Nasdaq and to
the extent correct, that it has not yet completed an initial business combination. On
page 137, please also expand your disclosures regarding Altitude Acquisition Corp. to
disclose the formation date of the SPAC and information regarding any initial
business combination.
Initial Business Combination, page 9
9.We note disclosure on page 33 and elsewhere regarding payments of various fees that
may be made to insiders, including your sponsor, officers, directors and their
affiliates, and the amount of contemplated fees reflected in your Use of Proceeds
table. Please revise your compensation table on page 10 to reference the potential
payments that may be made to your sponsor, its affiliates or promoters of finder's,
advisory, consulting or success fees for their services rendered prior to or in
connection with the completion of the initial business combination. Please also
disclose the anti-dilution adjustment of the founder shares in the table. Also describe
the extent to which any compensation or securities issuance to the sponsor, its
affiliates or promoters may result in a material dilution of the purchasers’ equity
interests. See Items 1602(b)(6) and 1603(a)(6) of Regulation S-K.
10.Please revise your tabular disclosure beginning on page 10 regarding transfer
restrictions to identify the natural persons and entities subject to such agreements. See
Item 1603(a)(9) of Regulation S-K.
Conflicts of Interest, page 22
11.Please expand your disclosures to describe all such actual or potential material
conflicts between the sponsor, its affiliates, or promoters, and purchasers in the
offering, including those that may arise in determining whether to pursue a de-SPAC
transaction. For example, you should discuss potential material conflicts relating to
compensation, the financial interests of the sponsor, its affiliates and promoters in
completing any de-SPAC transaction within the allotted time, repayment of loans, as
well as the fact that the company may pursue a de-SPAC transaction with a target that
is affiliated with the sponsor, its affiliates or promoters. Please see Item 1602(b)(7)
and Item 1603(b) of Regulation S-K.
Ability to extend time to complete initial business combination, page 24
12.Please disclose whether security holders will have voting or redemption rights with
respect to an extension. In addition, please disclose your plans if you do not
consummate a de-SPAC transaction within 24 months, including whether you expect
to extend the time period, whether there are any limitations on the number of
extensions, including the number of times, and the consequences to the SPAC sponsor
of not completing an extension of this time period. See Item 1602(b)(4) of Regulation
S-K.
Expressions of interest, page 24
Please disclose the number of non-managing sponsor investors who have expressed an
interest in purchasing units and whether you believe these purchases will affect your 13.

December 15, 2024
Page 4
ability to meet Nasdaq listing requirements. Please file any agreements or forms of
agreements with the non-managing sponsor investors as exhibits or advise us why
they are not material.
Anticipated expenses and funding sources, page 26
14.Please revise this section or include a new section within the Summary under an
appropriate subcaption to provide a more comprehensive discussion regarding
whether you have any plans to seek additional financing and how such financings
may impact unaffiliated security holders, as required by Item1602(b)(5) of Regulation
S-K. In this regard, we note your disclosures that you intend to effectuate your initial
business combination using among other sources, your shares, debt, or a combination
that includes shares and debt, and that you intend to target businesses whose
enterprise value is up to $2.0 billion.
Summary Financial Data, page 36
15.Please tell us why the $204,600 over-allotment liability has been included in total
liabilities, as adjusted, but not included in the calculation of working capital (deficit),
as adjusted.
Risk Factors
If we seek shareholder approval of our initial business combination . . . , page 47
16.Please expand your risk factor to also explain that no votes from public shares would
be needed if only the holders required for quorum were to vote, as you disclose on
page 20 and elsewhere, or if the non-managing sponsor investors vote in favor of the
initial business combination, as you discuss on page 24. In addition, here and where
similar disclosure appears, revise to discuss the incentive that such non-managing
sponsor investors will have to vote in favor of the transaction. Please also add or
revise the fourth summary risk factor on page 37 to explain these scenarios.
We may not be able to complete an initial business combination. . ., page 81
17.With a view towards disclosure, please state whether your sponsor is, is controlled by,
or has substantial ties with a non-U.S. person. If so, please expand this risk factor to
discuss this information.
Dilution, page 97
18.We note your disclosure on page 59 stating that you do not have a specified maximum
redemption threshold.  Please reconcile this with the fact that you have limited the
number of ordinary shares to be redeemed in the maximum redemption scenarios
calculated on page 98.  We also note that the amount paid for redemptions in the
maximum redemption scenarios is based on a per share price of $10.05, while the
amount paid for redemptions in other scenarios is $10 per share.  Please advise.
We note that your calculations assume that you will not issue any ordinary shares as
part of the combination consideration, and that no ordinary shares and convertible
equity or debt securities are issued in connection with additional financing in
connection with an initial business combination. Please expand your disclosure to
highlight that you may need to do so as you intend to target an initial business 19.

December 15, 2024
Page 5
combination with a target company whose enterprise value is up to $2.0 billion.
Proposed Business
Comparison of Redemption or Purchase. . ., page 127
20.We note your disclosures throughout your prospectus that your sponsor, directors,
officers, advisors or their affiliates may purchase shares in privately negotiated
transactions or in the open market transactions from public shareholders who have
already elected to exercise redemption rights or submitted a proxy to vote against your
initial business combination, and that the purpose of such purchases may result in the
completion of your initial business combination that may not otherwise have been
possible and your disclosure here that there is no limit to the prices that they may pay
for such purchases. Please revise to discuss how any such purchases would comply
with Rule 14e-5. Refer to Tender Offer Rules and Schedules C&DI 166.01.
Notes to the Financial Statements
Note 7, page F-15
21.We note your determination that the private placement warrants meet the
requirements for equity classification. Please provide us with your analysis under
ASC 815-40 to support your accounting treatment for these warrants. As part of your
analysis, please address whether there are any terms or provisions in the warrant
agreement that provide for potential changes to the settlement amounts that are
dependent upon the characteristics of the holder of the warrant, and if so, how you
analyzed those provisions in accordance with the guidance is ASC 815-40. Your
response should address, but not be limited to, your disclosure that "the Private
Placement Warrants will be non-redeemable for cash and exercisable on a cashless
basis so long as they are held by the Sponsor or its permitted transferees."
General
22.We note your disclosures that you have 24 months to consummate an initial business
combination, but that you may hold a shareholder vote to amend such duration, "as
well as to modify the substance or timing of [y]our obligation to redeem 100% of
[y]our public shares." Please revise to clarify what you mean by this phrase and also
how any such amendment will comply with the requirements of Nasdaq Rule 5101-
2(d).

December 15, 2024
Page 6
            Please contact Kellie Kim at 202-551-3129 or Kristina Marrone at 202-551-3429 if
you have questions regarding comments on the financial statements and related
matters. Please contact Pearlyne Paulemon at 202-551-8714 or Dorrie Yale at 202-551-8776
with any other questions.
Sincerely,
Division of Corporation Finance
Office of Real Estate & Construction
cc:Michael J. Blankenship